Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Activated CIK and anti-CD3-MUC1 bispecific antibody in advanced liver cancer
NCT03484962Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anti-CD3-MUC1 bispecific antibody in hepatocellular carcinoma (HCC) (3 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Objective Response Rate at 1 year. Planned start Mar 2018; status: withdrawn.
02
Drugs
anti-CD3-MUC1 bispecific antibody
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03484962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484962.